vs

Side-by-side financial comparison of Citizens Community Bancorp Inc. (CZWI) and NewAmsterdam Pharma Co N.V. (NAMS). Click either name above to swap in a different company.

NewAmsterdam Pharma Co N.V. is the larger business by last-quarter revenue ($19.1M vs $15.8M, roughly 1.2× Citizens Community Bancorp Inc.). Citizens Community Bancorp Inc. runs the higher net margin — 27.1% vs -90.7%, a 117.8% gap on every dollar of revenue. On growth, NewAmsterdam Pharma Co N.V. posted the faster year-over-year revenue change (740.1% vs 14.9%). Citizens Community Bancorp Inc. produced more free cash flow last quarter ($10.4M vs $-37.8M).

Glacier Bancorp, Inc. is a regional multi-bank holding company headquartered in Kalispell, Montana, United States. It is a successor corporation to the Delaware corporation originally incorporated in 1990. The company provides personal and commercial banking services from 221 locations in Montana, Idaho, Utah, Washington, Wyoming, Colorado, Arizona, and, Nevada.

Kite Pharma, Inc. is an American biotechnology company that develops cancer immunotherapy products with a primary focus on genetically engineered autologous CAR T cell therapy - a cell-based therapy which relies on chimeric antigen receptors and T cells. Founded in 2009, and based in Santa Monica, California, it was acquired by Gilead Sciences in 2017.

CZWI vs NAMS — Head-to-Head

Bigger by revenue
NAMS
NAMS
1.2× larger
NAMS
$19.1M
$15.8M
CZWI
Growing faster (revenue YoY)
NAMS
NAMS
+725.2% gap
NAMS
740.1%
14.9%
CZWI
Higher net margin
CZWI
CZWI
117.8% more per $
CZWI
27.1%
-90.7%
NAMS
More free cash flow
CZWI
CZWI
$48.1M more FCF
CZWI
$10.4M
$-37.8M
NAMS

Income Statement — Q4 FY2025 vs Q2 FY2025

Metric
CZWI
CZWI
NAMS
NAMS
Revenue
$15.8M
$19.1M
Net Profit
$4.3M
$-17.4M
Gross Margin
Operating Margin
31.0%
-186.1%
Net Margin
27.1%
-90.7%
Revenue YoY
14.9%
740.1%
Net Profit YoY
58.1%
55.5%
EPS (diluted)
$0.44
$-0.15

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CZWI
CZWI
NAMS
NAMS
Q4 25
$15.8M
Q3 25
$16.2M
Q2 25
$16.1M
$19.1M
Q1 25
$14.2M
Q4 24
$13.7M
$12.8M
Q3 24
$14.2M
$29.1M
Q2 24
$13.5M
Q1 24
$15.2M
Net Profit
CZWI
CZWI
NAMS
NAMS
Q4 25
$4.3M
Q3 25
$3.7M
Q2 25
$3.3M
$-17.4M
Q1 25
$3.2M
Q4 24
$2.7M
$-92.2M
Q3 24
$3.3M
$-16.6M
Q2 24
$3.7M
Q1 24
$4.1M
Operating Margin
CZWI
CZWI
NAMS
NAMS
Q4 25
31.0%
Q3 25
27.9%
Q2 25
25.1%
-186.1%
Q1 25
28.0%
Q4 24
24.5%
-338.5%
Q3 24
29.5%
-85.9%
Q2 24
35.0%
Q1 24
34.2%
Net Margin
CZWI
CZWI
NAMS
NAMS
Q4 25
27.1%
Q3 25
22.7%
Q2 25
20.3%
-90.7%
Q1 25
22.5%
Q4 24
19.7%
-721.7%
Q3 24
23.1%
-57.2%
Q2 24
27.2%
Q1 24
26.9%
EPS (diluted)
CZWI
CZWI
NAMS
NAMS
Q4 25
$0.44
Q3 25
$0.37
Q2 25
$0.33
$-0.15
Q1 25
$0.32
Q4 24
$0.28
$-0.91
Q3 24
$0.32
$-0.18
Q2 24
$0.35
Q1 24
$0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CZWI
CZWI
NAMS
NAMS
Cash + ST InvestmentsLiquidity on hand
$118.9M
$739.2M
Total DebtLower is stronger
$51.8M
Stockholders' EquityBook value
$187.9M
$778.5M
Total Assets
$1.8B
$815.1M
Debt / EquityLower = less leverage
0.28×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CZWI
CZWI
NAMS
NAMS
Q4 25
$118.9M
Q3 25
$82.4M
Q2 25
$67.5M
$739.2M
Q1 25
$100.2M
Q4 24
$50.2M
$834.2M
Q3 24
$36.6M
$422.7M
Q2 24
$36.9M
Q1 24
$28.6M
Total Debt
CZWI
CZWI
NAMS
NAMS
Q4 25
$51.8M
Q3 25
Q2 25
Q1 25
Q4 24
$66.6M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
CZWI
CZWI
NAMS
NAMS
Q4 25
$187.9M
Q3 25
$186.8M
Q2 25
$183.5M
$778.5M
Q1 25
$180.1M
Q4 24
$179.1M
$757.5M
Q3 24
$180.1M
$378.9M
Q2 24
$176.0M
Q1 24
$172.8M
Total Assets
CZWI
CZWI
NAMS
NAMS
Q4 25
$1.8B
Q3 25
$1.7B
Q2 25
$1.7B
$815.1M
Q1 25
$1.8B
Q4 24
$1.7B
$864.6M
Q3 24
$1.8B
$439.2M
Q2 24
$1.8B
Q1 24
$1.8B
Debt / Equity
CZWI
CZWI
NAMS
NAMS
Q4 25
0.28×
Q3 25
Q2 25
Q1 25
Q4 24
0.37×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CZWI
CZWI
NAMS
NAMS
Operating Cash FlowLast quarter
$11.7M
$-37.7M
Free Cash FlowOCF − Capex
$10.4M
$-37.8M
FCF MarginFCF / Revenue
65.9%
-197.2%
Capex IntensityCapex / Revenue
8.3%
0.5%
Cash ConversionOCF / Net Profit
2.74×
TTM Free Cash FlowTrailing 4 quarters
$17.5M
$-119.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CZWI
CZWI
NAMS
NAMS
Q4 25
$11.7M
Q3 25
$6.6M
Q2 25
$-406.0K
$-37.7M
Q1 25
$1.6M
Q4 24
$20.4M
$-37.5M
Q3 24
$3.5M
$-12.5M
Q2 24
$5.1M
Q1 24
$9.1M
Free Cash Flow
CZWI
CZWI
NAMS
NAMS
Q4 25
$10.4M
Q3 25
$6.2M
Q2 25
$-632.0K
$-37.8M
Q1 25
$1.5M
Q4 24
$19.5M
$-37.5M
Q3 24
$3.4M
$-12.6M
Q2 24
$4.8M
Q1 24
$8.9M
FCF Margin
CZWI
CZWI
NAMS
NAMS
Q4 25
65.9%
Q3 25
38.4%
Q2 25
-3.9%
-197.2%
Q1 25
10.7%
Q4 24
142.2%
-293.5%
Q3 24
23.8%
-43.2%
Q2 24
35.7%
Q1 24
58.9%
Capex Intensity
CZWI
CZWI
NAMS
NAMS
Q4 25
8.3%
Q3 25
2.4%
Q2 25
1.4%
0.5%
Q1 25
0.7%
Q4 24
6.5%
0.0%
Q3 24
0.9%
0.3%
Q2 24
2.3%
Q1 24
1.4%
Cash Conversion
CZWI
CZWI
NAMS
NAMS
Q4 25
2.74×
Q3 25
1.80×
Q2 25
-0.12×
Q1 25
0.50×
Q4 24
7.55×
Q3 24
1.07×
Q2 24
1.39×
Q1 24
2.24×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons